Effects of Tanreqing combined with Moxifloxacin in treatment of COPD patients with pulmonary infection
Objective:To observe effects of Tanreqing combined with Moxifloxacin in treatment of patients with chronic obstructive pulmonary disease(COPD)complicated with pulmonary infection.Methods:A prospective study was conducted on 96 patients with COPD complicated with pulmonary infection admitted to the hospital from May 2021 to April 2023.According to the random number table method,they were divided into study group and control group,48 cases in each group.The control group was treated with Moxifloxacin,while the study group was treated with Tanreqing injection on the basis of that of the control group.The clinical efficacy,the levels of inflammatory factors[C-reactive protein(CRP),interleukin-6(IL-6),procalcitonin(PCT)],lung function indexes[forced expiratory volume in the first second(FEV1),forced vital capacity(FVC)]and T cell subsets indexes(CD3+,CD4+,CD8+)before and after the treatment,and the incidence of adverse reactions were compared between the two groups.Results:The total effective rate of the study group was 91.67%(44/48),which was higher than 77.08%(37/48)of the control group,and the difference was statistically significant(P<0.05).After the treatment,the levels of PCT,CRP and IL-6 in the two groups were lower than those before the treatment,those in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the levels of FEV1 and FVC in the two groups were higher than those before the treatment,those in the study group were higher than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the levels of CD3+and CD4+in the two groups were higher than those before the treatment,and those in the study group were higher than those in the control group;the levels of CD8+in the two groups were lower than those before the treatment,and that in the study group was lower than that in the control group;and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Tanreqing injection combined with Moxifloxacin in the treatment of the COPD patients with pulmonary infection can improve the therapeutic effects and the levels of pulmonary function indexes,improve the levels of T cell subsets and reduce the levels of inflammatory factors.Moreover,it is superior to simple Moxifloxacin treatment.
NETL
NSTL
万方数据
